Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YIV-906 |
Synonyms | |
Therapy Description |
YIV-906 (KD018) is an herbal formulation whose mechanism of action is unclear, but which results in inhibition of CYP3A4, MMP, NF-KB, beta-glucuronidase, and the NK-1 receptor, as well as modulation of certain cytokines, macrophages and lymphocytes (PMID: 25819872, PMID: 31617551). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YIV-906 | PHY906|KD018 | YIV-906 (KD018) is an herbal formulation whose mechanism of action is unclear, but which results in inhibition of CYP3A4, MMP, NF-KB, beta-glucuronidase, and the NK-1 receptor, as well as modulation of certain cytokines, macrophages and lymphocytes (PMID: 25819872, PMID: 31617551). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02178644 | Phase I | YIV-906 Capecitabine | Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer | Completed | USA | 0 |
NCT00730158 | Phase II | Irinotecan YIV-906 | A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |